NCT02568267: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: NTRK, ROS, ALK
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Solid tumors must harbor an NTRK1/2/3, ROS1, or ALK gene fusion; Diagnosis of NET not required, but NET patients are eligible
Exclusions: CNS involvement, including leptomeningeal carcinomatosis, which is symptomatic or uncontrolled
https://ClinicalTrials.gov/show/NCT02568267

Comments are closed.

Up ↑